NCT02518555 2026-04-06
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
6 trialsNCT02860039 2024-10-22
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT04591379 2022-12-13
Intratumoral Influenza Vaccine for Early Colorectal Cancer
Zealand University Hospital
Phase 2 Completed
NCT02566265 2019-01-30
SHIVERING 2
Yale University
Phase 2 Completed
NCT01205581 2016-09-23
Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV
St. Jude Children's Research Hospital
Phase 2 Completed
NCT01666782 2016-06-24
IMMUNE
Rochester General Hospital
Phase 2 Completed